Kunming Longjin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Kunming Longjin Pharmaceutical has a total shareholder equity of CN¥528.6M and total debt of CN¥1.0M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are CN¥597.4M and CN¥68.8M respectively.
Key information
0.2%
Debt to equity ratio
CN¥1.00m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥303.19m |
| Equity | CN¥528.62m |
| Total liabilities | CN¥68.75m |
| Total assets | CN¥597.37m |
Recent financial health updates
Recent updates
What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You
Aug 14
Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet
Jun 30Risks Still Elevated At These Prices As Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Shares Dive 26%
Apr 26We're Not Very Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Rate
Apr 17Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 29%
Mar 08Financial Position Analysis
Short Term Liabilities: 002750's short term assets (CN¥354.6M) exceed its short term liabilities (CN¥42.0M).
Long Term Liabilities: 002750's short term assets (CN¥354.6M) exceed its long term liabilities (CN¥26.7M).
Debt to Equity History and Analysis
Debt Level: 002750 has more cash than its total debt.
Reducing Debt: 002750's debt to equity ratio has increased from 0% to 0.2% over the past 5 years.
Debt Coverage: 002750's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 002750's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 11:39 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kunming Longjin Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |